New Formulations Will Speed Discovery of Biomarkers and Precision Therapies
MINNEAPOLIS, Feb. 05, 2020 (GLOBE NEWSWIRE) — TumorGenesis, Inc. a subsidiary of Predictive Oncology, Inc. (NASDAQ: POAI) has selected US Biological Corporation of Salem, Massachusetts as the manufacturer and distributor of its innovative culture media for growing ovarian tumor cells.Unlike traditional cell culture media, which select for one or two fast growing cell types, TumorGenesis media are specially formulated to help researchers isolate and maintain the unique histological and basic biological signatures of heterogeneous ovarian cell types while growing them in the laboratory.   “Using these proprietary media our partners have identified 25 cell types from ovarian tumors, which to a large degree have never been screened or studied by researchers,” said Richard Gabriel, President of TumorGenesis, Inc. “The resulting cells have a 95+% match to cells found in patient bodies.”Available for purchase via US Biological in Q1-2020, the new media are being launched at a time when, according to MarketWatch, the global cell culture media market is growing at a healthy 8.4% CAGR, driven mainly by the increased use of biological based drugs such as immune therapies, and is expected to reach US $2,360 Million by 2024.While specialty media is a small subset of the market, Gabriel sees this ovarian-specific formulation as the first in a portfolio of tools and services TumorGenesis will offer to cancer researchers. “We believe by helping researchers develop cells and tumors that more closely mimic cells and tumor found in patient bodies, we can help lower the cost and speed the discovery of drugs and therapies that will approve patient outcomes.”About Predictive Oncology Inc.
Bay Street News